Aeglea BioTherapeutics Other Current Liabilities

The latest other current liabilities for AGLE is $79M as of March 2026. That compares with $63M in the prior-year period — up 25.5% year over year. Investors often review this figure alongside Aeglea BioTherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, AGLE's other current liabilities moved from $63M to $79M — a 25.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Aeglea BioTherapeutics's operating scale or balance-sheet position.

A other current liabilities figure of $79M for AGLE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AGLE's other current liabilities ($79M), review year-over-year change from $63M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Aeglea BioTherapeutics's other current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.